Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s (NASDAQ:REGN) effort to prevent the sale of Amgen Inc‘s (NASDAQ:AMGN) Eylea biosimilar.
Regeneron filed a notice of its appeal to the U.S. Court of Appeals for the Federal Circuit.
The appeal is from the Order issued on September 23, 2024, which denied Regeneron’s request for a preliminary injunction, along with any related orders, decisions, rulings, findings, or conclusions connected to that Order.
Reuters highlighted that an Amgen spokesperson expressed the company’s satisfaction with the decision. Amgen will reveal the ...
